Enterprise Value

102.7B

Cash

8.35B

Avg Qtr Burn

N/A

Short % of Float

1.82%

Insider Ownership

0.09%

Institutional Own.

88.38%

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Yescarta® Details
B-cell lymphoma, Lymphopenia

Approved

Quarterly sales

Trodelvy® (sacituzumab govitecan-hziy) Details
Cancer, Breast cancer, ER+/HER2- breast cancer

Approved

Quarterly sales

Approved

Quarterly sales

Approved

Quarterly sales

Approved

Quarterly sales

Tecartus® (brexucabtagene autoleucel) (CAR-T) Details
Leukemia, B-cell acute lymphoblastic leukemia, Acute lymphoblastic leukemia

Approved

Quarterly sales

Biktarvy Details
Human immunodeficiency virus

Approved

Quarterly sales

Seladelpar (MBX-8025) Details
Primary biliary cholangitis, Non-alcoholic steatohepatitis , Primary sclerosing cholangitis, Liver disease

Big Mover™

Susp. Mover™

PDUFA

Approval decision

Phase 3

Update

Sunlenca (Lenacapavir) Details
Human immunodeficiency virus

Phase 2/3

Data readout

Lenacapavir Details
Human immunodeficiency virus

Phase 2

Data readout

Phase 2

Data readout

Etrumadenant Details
Colorectal cancer

Phase 2

Data readout

Yescarta Details
Lymphopenia, B-cell lymphoma

Phase 2

Interim update

Phase 2

Update

Phase 2

Update

Magrolimab+Azacitidine Details
High risk myelodysplastic syndromes

Failed

Discontinued